Eli Lilly Narrows FY2026 Adj EPS Guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 Est; Raises FY2026 Sales Guidance from $82.000B-$85.000B to $85.000B-$87.000B vs $85.446B Est

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
Eli Lilly (NYSE: LLY) narrows FY2026 Adj EPS guidance from $35.50-$37.00 to $35.50-$35.60 vs $34.20 analyst estimate. Raises FY2026 sales outlook from $82.000 billion-$85.000 billion to $85.000 billion-$87.000 billion vs $85.446 billion estimate.
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.